DE69638119D1 - Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen - Google Patents

Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Info

Publication number
DE69638119D1
DE69638119D1 DE69638119T DE69638119T DE69638119D1 DE 69638119 D1 DE69638119 D1 DE 69638119D1 DE 69638119 T DE69638119 T DE 69638119T DE 69638119 T DE69638119 T DE 69638119T DE 69638119 D1 DE69638119 D1 DE 69638119D1
Authority
DE
Germany
Prior art keywords
compositions
lean meat
meat mass
increasing lean
obesity protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638119T
Other languages
German (de)
English (en)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE69638119D1 publication Critical patent/DE69638119D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69638119T 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen Expired - Lifetime DE69638119D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
DE69638119D1 true DE69638119D1 (de) 2010-03-11

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Country Status (15)

Country Link
EP (3) EP0866720B1 (enExample)
JP (2) JP4173914B2 (enExample)
AT (2) ATE455554T1 (enExample)
AU (3) AU7607496A (enExample)
CA (2) CA2236163A1 (enExample)
DE (2) DE69638119D1 (enExample)
DK (1) DK0866720T3 (enExample)
ES (2) ES2339846T3 (enExample)
IL (2) IL124442A0 (enExample)
MX (1) MX9803992A (enExample)
NZ (3) NZ512083A (enExample)
PT (1) PT866720E (enExample)
SI (1) SI0866720T1 (enExample)
WO (1) WO1997018833A1 (enExample)
ZA (1) ZA969605B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU2246097A (en) * 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
WO1997039767A1 (en) * 1996-04-19 1997-10-30 Zymogenetics, Inc. Methods for inducing bone formation
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
ATE351910T1 (de) * 1996-12-20 2007-02-15 Amgen Inc Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1128840A1 (en) * 1998-10-27 2001-09-05 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
ES2257287T3 (es) * 1999-02-12 2006-08-01 Amgen Inc. Composiciones de leptina glicosiladas y metodos relacionados.
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
JPH09503973A (ja) * 1993-08-13 1997-04-22 プッツマイスター・ヴェルク マシーネンファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング 大型対象物の表面を処理する方法および装置
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
ATE351910T1 (de) * 1996-12-20 2007-02-15 Amgen Inc Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Also Published As

Publication number Publication date
WO1997018833A1 (en) 1997-05-29
EP0956862A1 (en) 1999-11-17
NZ527007A (en) 2005-01-28
MX9803992A (es) 1998-09-30
AU7607496A (en) 1997-06-11
JP2000500492A (ja) 2000-01-18
JP4173914B2 (ja) 2008-10-29
EP0866720B1 (en) 2004-02-11
ZA969605B (en) 1997-06-02
DE69631544T2 (de) 2004-12-23
AU763755B2 (en) 2003-07-31
IL127926A (en) 2006-08-20
EP0866720A1 (en) 1998-09-30
NZ511617A (en) 2003-08-29
JP2002206000A (ja) 2002-07-23
ES2339846T3 (es) 2010-05-26
JP4227325B2 (ja) 2009-02-18
EP1285664A3 (en) 2003-07-30
EP1285664A2 (en) 2003-02-26
CA2236163A1 (en) 1997-05-29
NZ512083A (en) 2003-02-28
DK0866720T3 (da) 2004-06-14
PT866720E (pt) 2004-06-30
AU763769B2 (en) 2003-07-31
EP1285664B1 (en) 2010-01-20
AU4265200A (en) 2000-09-21
IL124442A0 (en) 1998-12-06
CA2358862A1 (en) 1997-05-29
AU4265300A (en) 2000-09-07
IL127926A0 (en) 1999-11-30
DE69631544D1 (de) 2004-03-18
ES2217327T3 (es) 2004-11-01
ATE259243T1 (de) 2004-02-15
ATE455554T1 (de) 2010-02-15
SI0866720T1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
DE69638119D1 (de) Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
DE69022163D1 (de) Steriles erzeugnis und verfahren zur sterilisierung und zusammenbau dieses erzeugnisses.
FI963315L (fi) Laite, menetelmä ja apuvälineet ihmisen tai eläimen kova- tai pehmytkudosten ja hampaan tai luun korvaavien materiaalien valmistamiseksi ultraäänen avulla ja siten aikaansaadut kohteet
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
AU1371995A (en) Method and apparatus for securing soft tissues, tendons and ligaments to bone
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE122467T1 (de) Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren.
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
EP0909172A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
ATE128872T1 (de) Gesteigerte erzeugung von proteinen in tieren.
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
AU7377296A (en) Method for treating hepatitis virus infection
ATA110696A (de) Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii
DE60128026D1 (de) Verfahren zur Beurteilung der Widerstandsfähigkeit gegen den Ausbruch von Leukämie bei Rindern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition